Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-Macrophage Migration Inhibitory Factor Antibody · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Malignant Solid Tumor (Arm 1) | EXPERIMENTAL | Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -\> 2. Safety data review. If dose escalation permissible -\> 3. Next dose group -\> 4. Safety data review, etc. Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s). |
| Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2) | EXPERIMENTAL | Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -\> 2. Safety data review. If dose escalation permissible -\> 3. Next dose group -\> 4. Safety data review, etc. Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s). |
| Name | Type | Description |
|---|---|---|
| Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody | BIOLOGICAL | * Dosing every 2 weeks * Intravenous injection |
Main Inclusion Criteria: * Males and females 18 years of age and older at the time of screening * Anticipated life expectancy \> 3 months at the time of screening * Arm 1 only: Histologically confirmed malignant solid tumor which is refractory to or has failed standard treatments, or participant is...
The anti-macrophage migration inhibitory factor antibody is being studied in metastatic adenocarcinoma of the colon or rectum and other malignant solid tumors. It is an oncology candidate developed by Takeda Pharmaceutical Company Limited under the ticker TAK. The clinical program enrolled adults aged 18 years and older across sites in the United States and Germany.
The anti-macrophage migration inhibitory factor antibody targets macrophage migration inhibitory factor, or MIF. It is a monoclonal antibody designed to bind that target. MIF is a protein implicated in tumor biology, and blocking it is the intended mechanism of this oncology candidate being developed by Takeda.
Takeda Pharmaceutical Company Limited, which trades under the ticker TAK, is the developer of the anti-macrophage migration inhibitory factor antibody. The company sponsored the Phase 1 study of the candidate in solid tumors. Takeda is a global pharmaceutical company with oncology among its therapeutic areas.
The anti-macrophage migration inhibitory factor antibody has completed a Phase 1 clinical trial. It is an investigational agent and is not approved for commercial use. The Phase 1 study evaluated the antibody in patients with metastatic adenocarcinoma of the colon or rectum and other malignant solid tumors, and it has finished enrollment and follow-up.
The anti-macrophage migration inhibitory factor antibody was evaluated in the Phase 1 study NCT01765790, titled Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors. That completed trial enrolled 68 patients with metastatic adenocarcinoma of the colon or rectum or other malignant solid tumors at sites in the United States and Germany.
Yes. The anti-MIF antibody and the anti-macrophage migration inhibitory factor antibody refer to the same monoclonal antibody candidate. MIF is the abbreviation for macrophage migration inhibitory factor, so the two names describe one agent developed by Takeda Pharmaceutical Company Limited for metastatic adenocarcinoma of the colon or rectum and other solid tumors.